title: Prognostic value of the International Scoring System and response in patients with advanced Waldenstrom macroglobulinemia.
authors.forename: Bénédicte
authors.initials: B
authors.lastname: Hivert
authors.forename: Jérome
authors.initials: J
authors.lastname: Tamburini
authors.forename: Anne
authors.initials: A
authors.lastname: Vekhoff
authors.forename: Olivier
authors.initials: O
authors.lastname: Tournilhac
authors.forename: Véronique
authors.initials: V
authors.lastname: Leblond
authors.forename: Pierre
authors.initials: P
authors.lastname: Morel
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D018450:Disease Progression; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D038801:International Classification of Diseases; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012008:Recurrence; D000069283:Rituximab; D013997:Time Factors; D016896:Treatment Outcome; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives; D008258:Waldenstrom Macroglobulinemia / Q000188:drug therapy*
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; D003520:Cyclophosphamide; D014740:Vidarabine; C024352:fludarabine